| 371.15 7.81 (2.15%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 450.03 | 1-year : | 525.63 |
| Resists | First : | 385.29 | Second : | 450.03 |
| Pivot price | 359.67  |
|||
| Supports | First : | 347.32 |
Second : | 323.85 |
| MAs | MA(5) : | 371.21  |
MA(20) : | 353.84 |
| MA(100) : | 333.79 |
MA(250) : | 337.18 |
|
| MACD | MACD : | 11.8 |
Signal : | 11.4 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 74.4 |
| RSI | RSI(14): 60.5 |
|||
| 52-week | High : | 414.14 | Low : | 275.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ WAT ] has closed below upper band by 33.3%. Bollinger Bands are 32% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 377.43 - 379.71 | 379.71 - 381.89 |
| Low: | 361.78 - 364.44 | 364.44 - 366.99 |
| Close: | 367.07 - 370.99 | 370.99 - 374.75 |
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.
Tue, 09 Jun 2026
New battery tester tracks heat, gas and voltage to spot failures - Stock Titan
Sun, 07 Jun 2026
What Waters (WAT)'s Diagnostics Wins and Q1 Beat Mean For Shareholders - simplywall.st
Wed, 03 Jun 2026
Kevin Hern acquires Waters Corporation stock through Hern Family Revocable Trust - Investing.com Nigeria
Mon, 01 Jun 2026
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics - PR Newswire
Tue, 26 May 2026
Are Wall Street Analysts Bullish on Waters Corporation Stock? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 98 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 99.6 (%) |
| Shares Short | 3,940 (K) |
| Shares Short P.Month | 3,730 (K) |
| EPS | 7.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 43 |
| Profit Margin | 11.9 % |
| Operating Margin | 2.8 % |
| Return on Assets (ttm) | 3.3 % |
| Return on Equity (ttm) | 5.2 % |
| Qtrly Rev. Growth | 91.4 % |
| Gross Profit (p.s.) | 21.18 |
| Sales Per Share | 38.39 |
| EBITDA (p.s.) | 11.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 390 (M) |
| Levered Free Cash Flow | -502 (M) |
| PE Ratio | 47.22 |
| PEG Ratio | 1.6 |
| Price to Book value | 8.62 |
| Price to Sales | 9.66 |
| Price to Cash Flow | 93.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|